Franco Poletti compensation by year
LivaNova Summary Compensation Table · the one fiscal year held| Component | FY2024 |
|---|---|
| Salary | $380,281 |
| Bonus | $0 |
| Stock awards | $835,501 |
| Option awards | $249,988 |
| Non-equity incentive | $426,894 |
| All other | $326,184 |
| Total | $2,218,848 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: LivaNova PLC DEF 14A filed April 30, 2025, accession 0001104659-25-041852, and prior-year filings.
How this page was built: the LivaNova PLC filed document, accession 0001104659-25-041852. Every figure is read from that document and cited to the page and table it appears in. Filed April 30, 2025.
Equity holdings
unvested awards at FY2024 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| PSU | 2,575 | $119,248 | — |
| RSU | 2,575 | $119,248 | — |
| RSU | 2,234 | $103,457 | — |
| PSU | 2,234 | $103,457 | — |
| PSU | 1,287 | $59,601 | — |
| PSU | 1,117 | $51,728 | — |
| RSU | 975 | $45,152 | — |
| RSU | 967 | $44,782 | — |
| RSU | 343 | $15,884 | — |
| RSU | 201 | $9,308 | — |
| Option | 829 | — | $82.04 |
| Option | 505 | — | $73.25 |
Per the Outstanding Equity Awards at Fiscal Year-End table in LivaNova PLC's FY2024 proxy; value at the fiscal year-end close, as the company printed it. The 12 largest of 15 award rows shown.
Insider transactions since the last proxy
16 Form 4 lines since the FY2024 proxy (filed April 30, 2025)current to 2026-11-21 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-03-30 | Exercise or conversion derivative | — | 558 | $0.00 | 1,117 |
| 2026-03-30 | Exercise or conversion derivative | — | 171 | $0.00 | 0 |
| 2026-03-30 | Exercise or conversion | — | 3,184 | $0.00 | 12,125 |
| 2026-03-30 | Tax withholding | — | 1,370 | $61.27 | 10,755 |
| 2026-03-30 | Exercise or conversion derivative | — | 325 | $0.00 | 325 |
| 2026-03-30 | Exercise or conversion derivative | — | 2,130 | $0.00 | 4,258 |
| 2026-03-11 | Exercise or conversion derivative | — | 2,140 | $0.00 | 0 |
| 2026-03-11 | Exercise or conversion | — | 2,140 | $57.60 | 10,990 |
The 8 most recent of 16 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
LivaNova’s named executive officers, FY2024
as the company reported each| Named executive officer | Role | FY2024 total |
|---|---|---|
| Vladimir Makatsaria | Chief Executive Officer | $9,710,672 |
| Alex Shvartsburg | Chief Financial Officer | $2,829,689 |
| Ahmet Tezel | Chief Innovation Officer | $2,773,543 |
| Trui Hebbelinck | Former CHRO | $2,492,978 |
| Michael Hutchinson | Chief Legal Officer | $2,406,874 |
| Franco Poletti · this page | President, Cardiopulmonary Business Unit | $2,218,848 |
| William Kozy | Former Interim CEO | $827,104 |
The full LivaNova compensation record
free company briefThis page is one person within LivaNova's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the LivaNova proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are LivaNova's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.